https://www.live-feeds.com/feed/mrna-cancer-vaccine-succeeded-in-phase-3-melanoma-trial-moderna-and-merck-sayContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/mrna-cancer-vaccine-succeeded-in-phase-3-melanoma-trial-moderna-and-merck-sayhttps://www.live-feeds.com/feed/mrna-cancer-vaccine-succeeded-in-phase-3-melanoma-trial-moderna-and-merck-say#u49050Wed, 26 Aug 2026 09:40:55 +0000Moderna and Merck's personalized mRNA cancer vaccine, paired with pembrolizumab, significantly reduced the risk of melanoma recurrence in a Phase 3 trial. The treatment is tailored to individual tumor mutations, marking a shift from one-size-fits-all approaches. The vaccine helped melanoma patients stay cancer-free longer. This success paves the way for potential FDA approval and a new approach to skin cancer treatment.Why it mattersMelanoma is a serious form of skin cancer with high recurrence rates. Current treatments often have varying degrees of success. The partnership between Modern https://www.live-feeds.com/feed/mrna-cancer-vaccine-succeeded-in-phase-3-melanoma-trial-moderna-and-merck-sayhttps://www.live-feeds.com/feed/mrna-cancer-vaccine-succeeded-in-phase-3-melanoma-trial-moderna-and-merck-say#u46019Fri, 21 Aug 2026 21:55:14 +0000Moderna and Merck announced that their personalized mRNA cancer vaccine significantly reduced the risk of melanoma returning during a phase 3 clinical trial. The treatment combines a neoantigen mRNA vaccine with the immunotherapy drug pembrolizumab. This successful trial represents the final clinical step required before the companies can seek FDA approval. The results suggest a shift toward treatments tailored to the specific mutations of individual tumors rather than a one-size-fits-all approach to skin cancer.Why it mattersMelanoma is a highly aggressive skin cancer prone to relapse. This t https://www.live-feeds.com/feed/mrna-cancer-vaccine-succeeded-in-phase-3-melanoma-trial-moderna-and-merck-sayhttps://www.live-feeds.com/feed/mrna-cancer-vaccine-succeeded-in-phase-3-melanoma-trial-moderna-and-merck-say#u45545Thu, 20 Aug 2026 12:01:15 +0000Moderna and Merck's mRNA cancer vaccine showed promise in a late-stage trial, preventing melanoma from returning. The vaccine, which uses Moderna's mRNA technology, achieved its primary goal in the Phase 3 trial. This development has significant implications for the treatment of melanoma and the use of mRNA technology in cancer therapy.Why it mattersMelanoma is a serious form of skin cancer that can be fatal if not treated promptly. Current treatments for melanoma include surgery, chemotherapy, and immunotherapy. The success of Moderna and Merck's mRNA cancer vaccine in a Phase